# This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.

> **NCT07649122** · PHASE3 · RECRUITING · sponsor: **Norroy Bioscience Co., LTD** · enrollment: 232 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DIAGNOSTIC_TEST:** 68-Ga-NYM032

## Key facts

- **NCT ID:** NCT07649122
- **Lead sponsor:** Norroy Bioscience Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-07-31
- **Target enrollment:** 232 (ESTIMATED)
- **Last updated:** 2026-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649122, "This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07649122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*